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Abstract
Tuberculosis (TB), a chronic communicable disease caused by the pathogen Mycobacterium
tuberculosis, has harassed the human being for long-term and remains to be one of the major public
health problems facing the world as well as the leading cause of death from a single infectious agent. We
are falling short of TB control targets set by the World Health Organization (WHO) and United Nations
(UN). To achieve the ambitious targets of global TB prevention and control, there is an urgent need for
immediate action as well as science and technology breakthroughs (e.g., a new vaccine and drug) to
rapidly reduce TB incidence worldwide. This study summarizes the current progress on global and China's
TB prevention and control, and analyzes the contribution of science and technology in TB prevention and
control. Based on the above analysis, we propose the following thought and advice on strengthening TB
prevention and control through science and technology:Strengthening the basic research of TB,
developing new TB vaccines and drugs, developing new diagnostic techniques for TB, and perfecting the
system to support and strengthen the safeguard measures. The purpose of this study is to promote the
policy layout and practice innovation of scientific prevention and control of TB in China, thus speeding up
the realization of goals set by the WHO End TB Strategy.
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Abstract: Tuberculosis (TB), a chronic communicable disease caused by the pathogen Mycobacterium tuberculosis,
has harassed the human being for a long time and remains to be one of the major public health problems facing the
world as well as a leading cause of death from a single infectious agent. We are falling short of TB control targets
set by the World Health Organization (WHO) and the United Nations (UN). To achieve the ambitious targets of
global TB prevention and control, there is an urgent need for immediate action as well as science and technology
breakthroughs (e.g., a new vaccine and drug) to rapidly reduce TB incidence worldwide. This study summarizes the
current progress on global and China’s TB prevention and control, and analyzes the contribution of science and
technology to TB prevention and control. On the basis of the above analysis, we propose the following advice on
strengthening TB prevention and control through science and technology: strengthening the basic research of TB,
developing new TB vaccines and drugs, developing new diagnostic techniques for TB, and perfecting the system to
support and strengthen the safeguard measures. The purpose of this study is to promote the policy layout and practice innovation of scientific prevention and control of TB in China, thus speeding up the realization of the goals set
by the WHO End TB Strategy. DOI: 10.16418/j.issn.1000-3045.20211116002-en
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Tuberculosis (TB), an ancient chronic communicable
disease caused by Mycobacterium tuberculosis (Mtb), has
been seriously threatening human health, particularly the
poor and the vulnerable. TB has killed more than 1 billion
people in the past 2000 years and kills about 1.5 million
people worldwide every year. The World Health Organization
(WHO) has put forward the End TB Strategy (2016–2035),
and the United Nations (UN) has also set the goals of containing TB and ending the TB epidemic by 2035 in Transforming Our World: The 2030 Agenda for Sustainable
Development. The deadlines set for these two goals are less
than 14 years and 9 years from now, respectively [1–3].
However, given the current trends and technologies, the goal
of eliminating TB may come into reality after 160 years in
2182 [4].
The most powerful weapon against infectious diseases is
science and technology. Therefore, the eventual defeat of TB,
an intractable chronic communicable disease, depends on
scientific development and technological innovation. The
priorities listed in Global Tuberculosis Report 2020 released
by WHO include a vaccine to lower the risk of infection, a
vaccine or new drug treatment to cut the risk of TB disease in
the approximately 2 billion people already infected, etc. [5]. If
no urgent action is taken to develop the relevant technologies,

the goals of containing TB worldwide may not be achieved.
This study summarizes the current progress in global and
China’s TB prevention and control, further analyzes the
contribution of science and technology in TB prevention and
control. Moreover, this study puts forward the following
recommendations on strengthening TB prevention and control through science and technology, including strengthening
basic research on TB, developing new TB vaccines and
drugs, developing new diagnostic techniques for TB, and
perfecting the system to support and strengthen the safeguard
measures. This study aims at promoting the policy layout and
practice innovation of scientific TB prevention and control in
China, thereby accelerating the realization of the goals in the
End TB Strategy.

1
1.1

Development trends of TB
Current status of TB in China and the world

According to the Global Tuberculosis Report 2021 issued
by WHO, there are 9.87 million newly diagnosed TB patients
worldwide in 2020 and the estimated incidence rate shows a
downward trend [6]. However, due to the impact of
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COVID-19 pandemic, a large number of TB patients are not
diagnosed and treated in time, which leads to an increase in
TB deaths from 1.408 million in 2019 to 1.494 million in
2020. This is the first increase in the past 15 years (Table 1).
Meanwhile, drug-resistant TB is still a severe global public
health crisis [6]. About 500 thousand rifampicin-resistant TB
(RR-TB) patients are reported worldwide in 2019 and 78% of
them are multidrug-resistant TB (MDR-TB) patients.
Moreover, the treatment success rate is 85% for
drug-susceptible TB worldwide but only 57% for
MDR/RR-TB. Notably, the COVID-19 pandemic has greatly
reduced the accessibility of health care and the visits of TB
patients. According to the model estimates, the global TB
prevention and control may be set back for 5–8 years due to
the outbreak of COVID-19 [5].
As one of the major countries harassed by TB for years,
China has become one of the 30 countries with high burdens
of TB, drug-resistant TB and TB/AIDS (HIV). The estimated
number of new TB patients in China is 842 thousand in 2020,
which ranks only second to India after ranking the third in
2019 [6] (Table 1). The burden of drug-resistant TB is particularly heavy in China. It is estimated that the new RR-TB
patients may be as high as 65 thousand per year, which ranks
the second worldwide. Moreover, more than 70% of the
drug-resistant TB patients have not been diagnosed in China,
which may pose high risks for human-to-human transmission
and great challenges for TB control [5]. In addition, there is a
large population with latent TB infection in China. A total of
365 million people has been infected with Mtb, which ranks
the second in the world [7]. These patients may develop into
active TB in their lifetime and thus it is of great significance
to adopt early and precise intervention against these latent
infection cases.

1.2 Goals and current situations of TB prevention
and control in the world
In 2014 and 2015, WHO member countries’ strategic goals
and the UN agenda for ending TB prevalence all include
specific milestones for reducing TB incidence and mortality,
and for eliminating catastrophic costs among TB patients and
their households [1,2]. On the first WHO Global Ministerial
Conference on TB in 2017, the Moscow Declaration to End
TB [7] was adopted. The UN General Assembly held the
first-ever high-level meeting on TB in 2018, which was
Table 1

attended by heads of different countries and governments as
well as other leaders. The meeting agreed on a political declaration, and reaffirmed and added new commitments to
Transforming Our World: The 2030 Agenda for Sustainable
Development and the End TB Strategy. Global targets were
set for the first time for the funding for TB prevention,
treatment and research, as well as for the number of Mtb
infections and patients treated [3].
The specific goals set by WHO and the UN for ending
global TB prevalence are as follows: the mortality and incidence of TB in 2030 should decrease by 90% and 80%, respectively, as compared with those in 2015; the mortality and
incidence in 2035 should decrease by 95% and 90%, respectively [1–3]. Although there have been some political declarations and great goals, the current progress is slow. The newly
diagnosed TB patients are still maintained at a stable level
every year in the recent five years. According to the Global
Tuberculosis Report 2021, most of the WHO member countries and the high TB burden countries did not achieve the
2020 milestones of the End TB Strategy. Moreover, the
COVID-19 pandemic has also caused tremendous negative
effect on TB prevention and control (Figure 1) [6].

2 Contribution of science and technology to
TB prevention and treatment
2.1 Achievements and challenges of TB prevention and control through science and technology in
China
TB patients may bring about heavy burdens for their families. A national survey reveals that the average out-of-pocket
financial burden for each TB patient is more than CNY 15
000 and about 1/4 TB patients become poor due to this disease. Therefore, TB prevention and control have become a
major challenge to the Healthy China initiative [8]. The CPC
Central Committee and the State Council of China have paid
additional attention to TB prevention and control and included it into the Outline of the Healthy China 2030 Plan in
2016. This is also an important step for China to fulfill its
commitment to achieving the targets in Transforming Our
World: the 2030 Agenda for Sustainable Development [9].
Additionally, China has issued a series of policies and taken

Global and China’s TB burden from 2016 to 2020

Data source: WHO Global Tuberculosis Report (2017–2021)(https://www.who.int/teams/global-tuberculosis-programme/tb-reports)
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Figure 1 Current situation and milestone progress towards targets set by WHO End TB Strategy and UN’s political declaration on fight
against TB [6].(a) WHO End TB Strategy: 2020 milestones; (b) UN high-level meeting on TB: Treatment targets; (c) UN high-level meeting
on TB: TB preventive treatment targets; (d) UN high-level meeting on TB: Funding targets

measures for TB prevention and control in recent years,
which has continuously reduced TB prevalence in China
(except for a slight rebound due to the impact of COVID-19
in 2020) [6,10] (Table 1). In addition to the management
measures, the ultimate achievement of the goals of TB prevention and control depends on the overall improvement of
science and technology. According to the National Mediumand Long-term Program for Science and Technology Development (2006–2020), the National Science and Technology Major Project “Prevention and Treatment of AIDS, Viral
Hepatitis and Other Major Infectious Diseases” approved by
the State Council and led and organized by National Health
Commisstion and the Health Bureau of Logistic Support
Department of the Central Military Commission of China
was launched in 2008. This project has achieved significant
progress during the 11th, 12th, and 13th Five-Year Plan periods. ① TB diagnosis. A number of new bacteriological,
immunological, and molecular biological techniques for
diagnosing TB have been developed, which have shortened
the time for detecting Mtb from 4–8 weeks to less than 6
hours, and increased the detection rate of Mtb in sputum from
①
25% to 50% . Moreover, the newly developed recombinant

Mtb fusion protein was applied in the screening of latent
infection cases, which improved the detection level among
the target population [11]. ② TB treatment. Because of the
large number of TB patients and the serious drug resistance, a
series of diagnostic products were developed and treatment
protocols were optimized for diagnosis and sustainable
treatment, which decreased the mortality rate of MDR-TB by
②
9% and made China a leading country in this field . ③
Research on TB vaccines. The TB vaccines AEC/BC02 and
Vaccae independently developed in China are among the 14
research projects on TB vaccines worldwide [5].
Despite the achievements mentioned above, there is still a
long way to go towards the goal of ending TB by 2035, and
the tasks of TB prevention and treatment in China are confronted with some major challenges, such as the lack of effective prevention measures. There is only one kind of
vaccine to prevent TB, which is the Bacillus Calmette-Guerin
(BCG). Because of its limited protective efficacy for adults,
breakthroughs are still required for developing new TB vaccines. China has a large population with latent TB infection,
which suggests an urgent need of appropriate immunological
intervention. Moreover, no effective screening method is
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① Ministry of Science and Technology of the People’s Republic of China. Press Conference of National Science and Technology Major Project “Prevention
and
Treatment
of
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and
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Infectious
Diseases”
(2018-03-27)[2021-11-29].
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② Ministry of Science and Technology of the People’s Republic of China. Communication materials for National Science and Technology Major Project
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(2016-01-11).
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available to identify people susceptible to TB, and the immunological mechanism of pathogen eradication among the
infected population remains unclear. Therefore, early
screening and effective protection measures cannot be carried
out effectively. Currently, the treatment of drug-resistant TB
patients depends on anti-TB medicines, whereas the treatment success rate of existing drugs for drug-resistant TB
patients is only 50% [12]. It is urgent to explore more effective
TB treatment methods, such as new therapeutic vaccines
based on novel mechanisms and strategies.

2.2 Progress and prospect of research in TB prevention and treatment
The basic research and applied research as well as the
development and application of innovative techniques may
provide a solid theoretical basis and strong technical support
for the prevention and treatment of TB. Here, the progress in
TB research is briefly introduced, including the progress in
basic research on TB, the discovery of new targets for TB
prevention and control, the development of new TB vaccines,
the research and development of new anti-TB medicines, and
new clinical treatment protocols for TB.

2.2.1 Basic research on TB and discovery of new
targets for TB prevention and treatment
The understanding of Mtb infection, disease onset, and
immune defense mechanism of hosts, as well as the discovery
of new targets and markers, are crucial for developing new
methods for TB prevention and treatment. The progress in the
basic research on TB in recent years are introduced in three
aspects as follows.
(1) Epidemiology and genomic characteristics of
drug-resistant TB. Systematic analysis of the epidemiology
and genomic characteristics of drug-resistant Mtb strains is
helpful for understanding the development trend of Mtb
resistance and providing new drug-resistant molecular
markers and new drug targets. ① Epidemiological analysis of
drug-resistant TB. Zhao et al. [13] have reported that
drug-resistant TB is prevalent in China after conducting a
survey on drug-resistant TB in China. The percentages of
MDR-TB cases in the new and recurrent TB cases were 5.7%
and 25.6%, respectively, and about 8% of the MDR-TB cases
were also extensively drug-resistant TB (XDR-TB) cases. ②
Genomic characteristics of drug-resistant Mtb strains. The
research group of Bi Lijun sequenced the whole genome and
transcriptome of 161 drug-resistant Mtb isolates from clinical
trials. After analyzing the data, they discovered 72 new
drug-resistant-associated genes and 28 intergenic regions
(IGRs), which provided a batch of new drug resistance
markers and drug targets for the establishment of new TB
drug resistance detection methods and the drug research and
development [14].
(2) Mechanisms of immune responses to TB. The interaction between Mtb and host immune system determines the
outcome of infection. The major achievements in this

research field are as follows. ① The immune escape mechanism of Mtb. The research groups of Liu Cui Hua, Gao
George Fu, and Qiu Xiao Bo jointly reported the novel
mechanism for PtpA, a Mtb effector protein, in promoting
intracellular survival of pathogens by inhibiting innate immunity through host ubiquitin [15]. They unraveled the
mechanism of the Mtb surface protein Rv1468c in recruiting
host ubiquitin to trigger host xenophagy, thus regulating the
intensity of inflammatory immune response of hosts [16].
Moreover, they revealed the new mechanism of PknG, a Mtb
effector protein, in suppressing innate immunity through
exerting unusual ubiquitinating enzyme activity and promoting pathogen intracellular survival by blocking autophagic flow via different domains and kinase activity [17,18].
The research groups of Ge Baoxue and Rao Zihe discovered a
mechanism of the host E3 ubiquitin ligase ANAPC2 in
damaging host immune responses via the ubiquitination of
Mtb Rv0222 [19]. ② The immune mechanism of hosts for
anti-Mtb infection. Khan et al. [20] revealed that Mtb infection
can activate type I interferon/iron axis, inhibit bone marrow
formation and impair protective trained immunity, which is
against the protective trained immunity induced by BCG,
suggesting a new immune escape strategy for pathogens in
bone marrow-derived macrophages. Ji et al. [21] analyzed the
correlation between type I interferon and TB susceptibility,
further proving that IL-1α is an important regulator for TB
susceptibility driven by type I interferon in vivo. Scheuermann et al. [22] analyzed the dynamic changes and interacting
molecules of platelets in lung tissues during the pathogenesis
of TB, suggesting that it was possible to reshape pulmonary
immune responses by regulating innate immune responses.
(3) Action mechanisms and structures of TB drug targets.
Important progress has been made in the action mechanisms
and structures of TB drug targets in China and other countries. For example, the research group led by Zhang Ying
reported RpsA, the first target of the first-line drug pyrazinamide for TB, and further revealed the molecular mechanism of pyrazinamide in killing Mtb with RpsA by inhibiting
protein translation of Mtb, shedding light on further selection
of drug candidates for TB [23]. Rao Zihe and his colleagues
analyzed the structures of EmbA-EmbB and EmbC-EmbC
complexes, targets of ethambutol and further confirmed the
drug target and molecular mechanism of ethambutol,
providing a theoretical basis for optimizing ethambutol and
developing new Emb-targeting drugs [24]. Rempel et al. [25]
confirmed that Rv1819c was the transport protein for vitamin
B12 (cobalamin), suggesting that Rv1819c may serve as an
ideal target for TB drugs. Moreover, they analyzed the
three-dimensional crystal structure of Mtb Rv1819c. Guo et
al. [26] revealed the three-dimensional image of bedaquiline
inhibiting the activity of adenosine triphosphate (ATP),
shedding light on the structural modification on TB drugs.

2.2.2 Development of new TB vaccines
BCG, the only licensed TB vaccine, is insufficient to

© 2022 China Academic Journals (CD Edition) Electronic Publishing House Co., Ltd.

4

contain the global TB prevalence. Although BCG can provide moderate or good protection for infants and prevent
severe TB, it does not protect adolescents and adults, the
major population among which TB is transmitted. Therefore,
it is in great need to develop new more effective TB vaccines.
Currently, at least 14 vaccine candidates are under clinical
development [5]. Tait et al. [27] reported that the results of a
phase IIb clinical trial of the novel protein-adjuvant vaccine
M72/AS01E which showed about 50% protection for people
with latent TB infection. This vaccine has been approved for
use in some low-income countries. In addition, several TB
vaccines are in the preclinical stage. Some studies have attempted to improve immune protection by changing the
vaccination routes. A study found that 9 out of 10 macaques
with Mtb infection did not develop active TB after receiving
intravenous BCG, with 6 out of 10 macaques showing no
detectable levels of infection [28]. Another study showed that
single-dose mucosal immunization with chimpanzee adenovirus-based vaccine accelerated TB control and limited its
rebound after antibiotic cessation [29]. Although these studies
provide new insights for improving the efficacy of TB vaccines, the available candidate vaccines seldom show antigenic and immunological diversity. Consequently, there is an
urgent need to develop new vaccines that work in multiple
ways, especially new TB vaccines that prevent initial infection (before exposure) or the development of disease (after
exposure).

2.2.3 Research and development of new TB drugs
The research and development of new TB drugs are lagging behind worldwide. With the growing attention to infectious diseases in recent years, China and other countries have
been developing new TB drugs under research or on clinical
trials. At present, the cure rate of susceptible TB is about
85%, while that of drug-resistant TB is only 34%–55%. In
addition, the treatment of drug-resistant TB patients requires
at least 9–20 months of second-line drug therapy. Therefore,
the research and development of new drugs for drug-resistant
TB patients have always been a major concern worldwide.
Three new drugs (bedaquiline, delamanid, and pretomanid)
have been approved in some regions for the treatment for
drug-resistant TB. However, these drugs have such limitations as inadequate efficacy and high toxicity, which can only
be used as a part of combination regimens. Some TB drugs
are still in preclinical and clinical trials. For example,
WQ-3810, a new fluoroquinolone drug against drug-resistant
developed by Ouchi et al. [30], can act on Mtb DNA helicases.
Telacebec (Q203) is another new TB drug, which is developed by de Jager et al. [31]. It targets Mtb cellular energy
metabolism through inhibiting the cytochrome bc1 complex.
The preliminary results from phase II clinical trials on
Telacebec showed that it had good in vitro and in vivo anti-Mtb activity. Although significant progress has been
achieved, the resistance to TB drugs is inevitable. Therefore,
more effective and low-toxicity anti-TB drugs are required to
cope with the unceasing emergence of drug-resistant TB.

2.2.4 New clinical treatment protocols for TB
In the current stage when the research and development of
TB drugs lags far behind clinical demand, the optimization of
clinical treatment protocols for TB is one of the effective
measures to improve TB prevention and control. The major
progress is as follows. Abidi et al. [32] systematically compared the effectiveness of a standardized short regimen (9–12
months) and a traditional long regimen (18–20 months or
longer). They found that the treatment success rate of the
short regimen (80.0%) was higher than that of the long
regimen (75.3%). Conradie et al. [33] reported a regimen with
three oral drugs (bedaquiline, delamanid, and pretomanid) in
South Africa for patients with XDR/MDR-TB. The results
showed that the treatment completion rate of this regimen
was higher, with the treatment success rate of 90%, which
was not inferior to the traditional regimen. Franke et al. [34]
reported a short-term clinical cohort study involving 1 109
patients with drug-resistant TB in multiple countries by using
bedaquiline and (or) delamanid. The results showed that 85%
of the patients turned negative in sputum test within six
months of treatment, compared with 73% for HIV-infected
people and 84% for non-HIV-infected people.
To sum up, the research on TB has received increasing
attention and achieved impressive progress. We are also
pleased to see that a series of original and leading research
results with great influence have been produced in China in
recent years. However, it should be noticed that the scientific
and technological support for TB prevention and control is
still insufficient in China, while the technological supply is
far from enough. Therefore, it is necessary to strengthen the
overall research layout on TB in China, so as to better assist
TB prevention and treatment through science and
technology.

3 Thoughts and recommendations on TB
prevention and treatment through science and
technology
Despite the progress in TB prevention and control in the
world, countries, and regions, efforts should be made to further strengthen the measures to prevent and treat TB through
science and technology. As a major country harassed by TB,
China is still confronted with the challenges in TB prevention
and treatment. The main challenge is that the scientific and
technological innovation based on new mechanisms, theories
and strategies is still insufficient. To thoroughly implement
the national strategy for people’s life and health, to achieve
breakthroughs in the prevention and control of TB via science
and technology during the 14th Five-Year Plan period, and to
provide strong support for building up the science and technology of China, we need to perfect the top-level design as
soon as possible, develop systematic layout of science and
technology, make efforts to tackle key problems, and develop
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new technologies and new methods for TB control with independent intellectual property rights. This study puts forward five suggestions for the prevention and treatment of TB
through science and technology in China.

The pathogenesis of TB is complex and closely related to
host immunity and metabolism, while there is still a lack of
comprehensive and in-depth understanding of the pathogenesis of TB. It is suggested to strengthen the research on the
dynamic regulation mechanism of Mtb-host interaction and
on the protective immune mechanism against TB, so as to
provide new strategies and targets for the development of TB
vaccines and drugs. Moreover, TB is associated with autoimmune diseases (e.g., pulmonary nodules and inflammatory
bowel disease), metabolic diseases (e.g., diabetes), and tumors. People with such diseases are often susceptible to TB.
Therefore, TB and the comorbidities may have common
mechanisms of pathogenesis. The studies of common
mechanisms for pathogenesis of TB and the comorbidities
may reveal the molecular markers of TB, thus providing new
markers for screening high-risk people with latent infection.
Moreover, such studies may also provide new common prevention and treatment methods for TB and the comorbidities.

should be strengthened. In the research and development of
new TB drugs, efforts should be made to improve the effectiveness against drug-resistant TB and reduce the occurrence
of drug resistance. Host-directed immunotherapy drugs are
one of the main research directions in the future. The
host-directed immunotherapy drugs can eliminate immune
escape and exhaustion caused by pathogens, improve the
protective immune responses of hosts, and reduce the tissue
damage caused by excessive inflammatory responses and
immunopathological responses. It is expected that
host-directed immunotherapy drugs may become one of the
important therapies against drug-resistant TB, and the combination with traditional antibiotic TB drugs may shorten the
course of treatment and reduce the occurrence of drug resistance. Therefore, it may be of great clinical value to
strengthen the studies about host immune mechanism upon
Mtb infection and develop host-based immunotherapy drugs
against TB. Moreover, on the basis of the complex pathogenesis of TB and the characteristics of chronic infection,
efforts can be made to explore the role and mechanism of
Chinese herbal compound prescriptions and their components in TB prevention and treatment, and to investigate the
new therapies with integrated Chinese and western medicine
against TB.

3.2

3.4

3.1

Reinforcing basic research on TB

Developing new TB vaccines

TB vaccines can be used to prevent TB and may be utilized as immunotherapy agents to shorten the treatment time
of TB or reduce the risk of reoccurrence, thereby reducing the
development and spread of drug-resistant TB. Moreover, TB
vaccines can also be used against drug-resistant TB. By
preventing TB, the vaccines can reduce the need for antibiotics, thereby preventing the emergerce of drug-resistance.
The End TB Strategy calls for about 250 million US dollars a
year to advance the development of TB vaccines. However,
the average annual investment was only 95 million US dollars in 2005–2017 [5]. Given the continual TB prevalence and
serious drug resistance to Mtb, it is urgent to clarify the immune response characteristics of lung mucosa to Mtb infection, especially the protective immune mechanism against
Mtb infection, and to develop new TB vaccines with high
efficacy and safety based on new theories, strategies, and
targets. Meanwhile, more efforts should be made to explore
new immunological evaluation methods for vaccines and
develop new strategies to improve the protective efficacy and
durability of vaccines.

3.3

Developing new TB drugs

The treatment of drug-resistant TB depends on TB drugs.
However, the cure rate of existing drugs for drug-resistant TB
is still low, and the existing TB drugs may cause drug resistance to Mtb. China now faces the weak capacity in original TB drug development and low transformation rate of
research achievements. In the future, the research and development of new TB drugs based on new mechanisms

Developing new diagnostic techniques for TB

Early and timely diagnosis of TB is crucial for treating
patients as early as possible and reducing the spread of TB.
TB diagnostic methods and techniques require further improvement, especially those for drug-resistant TB and latent
TB infection. New diagnostic markers are urgently needed,
including blood markers that can distinguish between active
TB and latent TB infection and molecular detection targets of
drug-resistant genes. In terms of diagnostic techniques, immediate and portable detection techniques with higher sensitivity and specificity remain to be developed. In addition,
there is a lack of effective screening methods to identify
people susceptible to TB. The available screening methods
are mostly based on the association between mutation of a
gene locus and TB incidence, while the immunological
mechanism is unknown. Therefore, it is difficult to carry out
early screening and further take effective protective
measures. Meanwhile, since the mechanisms for TB susceptibility and pathogenesis are complex and affected by
many factors, integrated analysis and comparison of
multi-level omics (including genomics, proteomics, ubiquitination proteomics, and metabolomics) should be carried
out from a systematic, integrated, and dynamic perspective.
Moreover, we should explore the host markers capable of
dynamically indicating the progression of Mtb infection,
screen and verify the biological markers that can be used for
rapid detection and diagnosis of TB and for indicating the
incidence of latent infection, treatment, and prognosis of TB
patients.

© 2022 China Academic Journals (CD Edition) Electronic Publishing House Co., Ltd.

6

3.5 Perfecting the systems to support and reinforce safeguard measures
Science and technology are the basis for the WHO End TB
Strategy, while TB control through science and technology
requires innovative environment and resources.
(1) Creating a favorable environment for scientific research and technological innovation for TB. We should formulate policies to encourage new models of collaborative
research and strengthen partnerships between government
and social capitals. Moreover, we should support the sharing
of intellectual property rights and resources (such as samples
and data), and simplify and unify research review and product
supervision procedures to carry out research consistently and
efficiently and rapidly transform research achievements. In
addition, financial and non-financial incentive measures
should be adopted to stimulate innovation at all levels including basic research, technology development, and
achievement transformation.
(2) Increasing financial investment in TB field. The basic
research on TB, research and development of vaccines and
drugs, and improvement of diagnostic techniques have long
lacked enough funding support. Moreover, the attraction of
the market is not enough to motivate enterprises to invest in
TB field. Therefore, it is urgent for the government to increase stable support for the basic research on TB, support the
unmet funding in the early stage of development of new
techniques and methods for TB diagnosis and prevention, and
encourage joint development of enterprises and other
developers.
(3) Promoting the cultivation of innovative talents in TB
field. The new techniques and methods for TB diagnosis,
prevention, and control depend on a comprehensive understanding of the pathogenesis and immune mechanism.
Therefore, it is suggested to promote talent cultivation for the
basic research and technological innovation, and encourage,
support, and cultivate well-trained innovative talents to continuously step up the original research on TB.

4

Conclusions

TB prevention and control in China are still confronted
with major challenges, but also are embracing great opportunities. China’s TB prevention and control through science
and technology has a bright prospect in the 14th Five-Year
Plan period. We should seize the opportunities, face the difficulties, and cooperate to accelerate the progress of TB prevention and control in China and contribute China’s power and
wisdom to the global goals for TB prevention and control.
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